β-lactam/β-lactamase inhibitor combinations: an update.
Sign Up to like & getrecommendations! Published in 2018 at "MedChemComm"
DOI: 10.1039/c8md00342d
Abstract: Antibiotic resistance caused by β-lactamase production continues to present a growing challenge to the efficacy of β-lactams and their role as the most important class of clinically used antibiotics. In response to this threat however,… read more here.
Keywords: lactamase inhibitors; class; inhibitor combinations; lactam lactamase ... See more keywords
Multidrug-resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel β-lactam-β-lactamase inhibitor combinations
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Anti-infective Therapy"
DOI: 10.1080/14787210.2021.1924674
Abstract: ABSTRACT Introduction: Multi-drug-resistant Klebsiella pneumoniae is currently one of the most pressing emerging issues in bacterial resistance. Treatment of K.pneumoniae infections is often problematic due to the lack of available therapeutic options, with a relevant… read more here.
Keywords: mechanisms resistance; pneumoniae; lactam lactamase; resistance ... See more keywords
In Vitro Activities of β-Lactam–β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01595-19
Abstract: We tested the in vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, piperacillin-tazobactam, and 11 other antimicrobial agents against 420 Burkholderia, Achromobacter, Stenotrophomonas, and Pandoraea strains, 89% of which were cultured from respiratory specimens from persons with… read more here.
Keywords: respiratory; cystic fibrosis; lactam lactamase; antimicrobial agents ... See more keywords
New β-Lactam–β-Lactamase Inhibitor Combinations
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Microbiology Reviews"
DOI: 10.1128/cmr.00115-20
Abstract: The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic… read more here.
Keywords: inhibitor combinations; lactam lactamase; lactamase inhibitor; drug ... See more keywords
The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Microbiology"
DOI: 10.1128/jcm.00807-21
Abstract: Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are among the newest β-lactam/β-lactamase inhibitors (BL/BLIs) introduced to the North American antibiotic market. All have broad Gram-negative activity, including against certain carbapenemases. ABSTRACT Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are among the… read more here.
Keywords: susceptibility testing; lactam lactamase; ins outs; gram negative ... See more keywords
The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
Sign Up to like & getrecommendations! Published in 2022 at "Antibiotics"
DOI: 10.3390/antibiotics11020277
Abstract: With the current crisis related to the emergence of carbapenem-resistant Gram-negative bacteria (CR-GNB), classical treatment approaches with so-called “old-fashion antibiotics” are generally unsatisfactory. Newly approved β-lactam/β-lactamase inhibitors (BLBLIs) should be considered as the first-line treatment… read more here.
Keywords: role colistin; treatment; lactam lactamase; carbapenem resistant ... See more keywords
Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United States
Sign Up to like & getrecommendations! Published in 2022 at "Antibiotics"
DOI: 10.3390/antibiotics11050660
Abstract: Antimicrobial resistance is a global public health threat, and gram-negative bacteria, such as Enterobacterales and Pseudomonas aeruginosa, are particularly problematic with difficult-to-treat resistance phenotypes. To reduce morbidity and mortality, a reduction in the time to… read more here.
Keywords: lactam lactamase; susceptibility testing; susceptibility; lactamase inhibitors ... See more keywords
Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15040463
Abstract: Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and results from phase… read more here.
Keywords: microbiological clinical; lactam lactamase; lactamase inhibitors; gram negative ... See more keywords